China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

000999

Rang in aandelen #2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Aandeelprijs
$3.74
Marktkapitalisatie
$6.23B
Verandering (1 dag)
-2.11%
Verandering (1 jaar)
-8.54%
Land
CN
Handel China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)

Categorie

Healthcare
Winst voor China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Winst in Jun 2026 TTM: $714.70M
Volgens de meest recente financiële verslagen van China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. bedraagt de huidige winst van het bedrijf $714.70M. In 2024 behaalde het bedrijf een winst van $629.34M, een stijging ten opzichte van de winst van 2023, die $530.39M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. van 2001 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $714.70M 2.80%
2025 $695.23M 10.47%
2024 $629.34M 18.65%
2023 $530.39M 37.94%
2022 $384.52M 21.98%
2020 $315.25M -14.08%
2019 $366.92M 46.83%
2018 $249.89M 7.08%
2017 $233.36M 11.49%
2016 $209.31M -11.11%
2015 $235.46M 15.78%
2014 $203.36M -9.34%
2013 $224.32M 8.45%
2012 $206.84M 37.53%
2011 $150.40M -4.00%
2010 $156.66M 18.25%
2009 $132.48M 39.94%
2008 $94.67M 79.81%
2007 $52.65M 60.01%
2006 $32.90M 52.20%
2005 $21.62M -126.33%
2004 $-82.11M -349.03%
2003 $32.97M 44.24%
2002 $22.86M 11.09%
2001 $20.58M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$3.62B 406.21%
DE
$3.40B 376.42%
DE
$1.72B 141.17%
JP
$930.30M 30.17%
CH
$1.69B 136.83%
IN